---
document_datetime: 2024-06-11 11:56:31
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/veltassa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: veltassa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 8.6044793
conversion_datetime: 2025-12-25 09:39:40.495671
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Veltassa

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                             |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034/G            | This was an application for a group of variations. · Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update safety information based on a pooled safety database. The Package Leaflet is updated accordingly. In addition, the MAH took the | 25/04/2024                          | 06/06/2024                                  | SmPC and PL                      | Update of sections 4.4 and 4.8 of the SmPC in order to reflect safety information based on a pooled safety database from study PAT-CR-302 (Diamond). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the PI. These changes do not significantly alter the safety profile of |

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|          | opportunity to implement editorial changes to the SmPC. · Update of section 4.8 of the SmPC in order to add 'Hypersensitivity' to the list of adverse drug reactions (ADRs) with frequency 'not known', based on post-marketing data. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                |            |            |                        | patiromer. Overall, the benefit-risk balance of Veltassa, remains positive.   |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------|
| X/0031/G | This was an application for a group of variations. Extension application to introduce a new strength (1 g powder for oral suspension), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of population from 12 to 17 years old for Veltassa based on final results from paediatric study RLY5016-206P (EMERALD); this is a phase 2, open-label, multiple dose study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer for oral suspension in children and adolescents 2 to less than 18 years of age with chronic kidney disease and hyperkalaemia. As a consequence, sections 1, 2, 4.1, 4.2, 4.4, 4.5, 4.8, | 09/11/2023 | 05/01/2024 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Veltassa EMEA/H/C/004180/X/0031/G\".    |

<div style=\"page-break-after: always\"></div>

|           | Labelling are updated in accordance. Version 2.3 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or approved one                                                                                                                                                                               |            |            |                 | Package Leaflet and modification of an   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------|
|           | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS                                                                                                                                                                                                             | 31/07/2023 | n/a        |                 | IB/0035/G                                |
| IA/0032/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 24/02/2023 | 15/05/2023 | Annex II and PL |                                          |

<div style=\"page-break-after: always\"></div>

|         | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                         |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0033 | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/02/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0029 | Update of sections 4.2 and 4.5 of the SmPC in order to introduce new drug-drug interaction information based on results from four in vitro studies: RLY-TR- 0174, titled 'In Vitro Evaluation of Potential RLY5016S and Immunosuppressant Drug-Drug Interactions'; RLY-TR-018, titled 'In Vitro Evaluation of Potential Drug-Drug Interactions Between Patiromer and Sevelamer Hydrochloride'; 'In Vitro Evaluation of Drug-Drug Interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS' and 'Drug-drug interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS in a simulated GI tract passage study'. The Package Leaflet is updated accordingly. | 06/10/2022 | 15/05/2023 | SmPC and PL | This variation concerns the update of the Product Information of Veltassa with the information from four drug-drug interaction studies. Section 4.2 SmPC recommendation remain in place, with only a minor wording amendment. Section 4.5 of the SmPC was updated with a list of medicinal products which did not demonstrate a binding potential in vitro. The advice that administration of patiromer should be separated by at least 3 hours from other oral medicinal products was maintained in the absence of clinical data to support. The MAH has also submitted an amended Package Leaflet to align the information with that in the SmPC. For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                        | Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0030 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                           | 24/05/2022 | 15/05/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0028    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27/01/2022 | 24/03/2022 | SmPC and Annex II      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Veltassa in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0024   | Update of section 4.2 of the SmPC in order to update the posology with information to add the option to use various liquids and soft foods instead of the currently approved options (water, apple, cranberry juice) for preparation of Veltassa oral suspension. This is based on results from a new compatibility study report of Veltassa with juices/liquids and soft foods (REP074062TC). The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 11/11/2021 | 24/03/2022 | SmPC and PL            | Results from a new compatibility study report of Veltassa with juices/liquids and soft foods (REP074062TC) concluded that the following liquids or soft foods can be used to prepare Veltassa oral suspension instead of water : apple juice, cranberry juice, pineapple juice, orange juice, grape juice, pear juice, apricot nectar, peach nectar, yoghurt, milk, thickener, apple sauce, vanilla and chocolate pudding. The mixture should be prepared following the described preparation mode included in the Product information updated accordingly. The potassium content of liquids or soft foods used to prepare the mixture should be considered as part of the dietary recommendations on potassium intake for each individual patient. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IB/0027   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 15/09/2021   | n/a   |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
| IA/0026   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 26/08/2021   | n/a   | procedure |
| IA/0025/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 27/07/2021   | n/a   |           |

<div style=\"page-break-after: always\"></div>

|                     | manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                       |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0023/G           | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished | 20/07/2021 | n/a |                                   |
| PSUSA/10618 /202010 | Periodic Safety Update EU Single assessment - patiromer                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/06/2021 | n/a | PRAC Recommendation - maintenance |
| IB/0022             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                         | 09/04/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0020             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                            | 18/12/2020   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0019             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                            | 27/11/2020   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0018             | Update of section 5.1 of the SmPC in order to update efficacy information based on final results from Study RLY5016-207; this is a randomised, double-blind, placebo-controlled, parallel group study of patiromer to enable concomitant spironolactone treatment in patients with resistant hypertension and CKD. Editorial changes are also made to Section 6.4 of the SmPC. The PI is also brought to the latest QRD version 10.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/10/2020   | 22/10/2021 | SmPC and Annex II | Of the randomized patients, 295 received study treatment (patiromer 147; placebo 148). The primary efficacy endpoint, the proportion of subjects remaining on spironolactone at Week 12, was significantly higher (p<0.0001) in the patiromer group (85.7%) compared to the placebo group (66.2%). Significantly more patients received spironolactone 50 mg/day (69.4% versus 51.4%). At Week 12, the mean systolic blood pressure had decreased by 11.0 mmHg (SD 15.34) in the spironolactone + placebo group and by 11.3 mmHg (SD 14.11) in the spironolactone + patiromer group. These decreases from baseline were statistically significant within each treatment group (p<0.0001), but not statistically significant between the groups. |
| PSUSA/10618 /201910 | Periodic Safety Update EU Single assessment - patiromer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/05/2020   | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0017             | B.I.c.z - Container closure system of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/05/2020   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0016             | B.I.b.1.z - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 11/03/2020   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0012/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold | 17/12/2019 | n/a |
| IA/0014/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 09/12/2019 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                  |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0013             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29/11/2019 | n/a |                                   |
| PSUSA/10618 /201904 | Periodic Safety Update EU Single assessment - patiromer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31/10/2019 | n/a | PRAC Recommendation - maintenance |
| IB/0010/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 03/07/2019 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007             | Update of section 4.2, and 5.1 of the SmPC to reflect the results of study RLY5016-401: an open-label, randomised, parallel group phase 4 study of the efficacy and safety of patiromer for oral suspension with or without food for the treatment of hyperkalemia (TOURMALINE). The PL has been updated accordingly. Section 4.5 was also updated to update information on the effect of patiromer on other medicinal products. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 02/05/2019 | 06/06/2019 | SmPC and PL | In the TOURMALINE open-label study, 114 patients with hyperkalaemia were randomized to patiromer once daily with food or without food. Serum potassium at the end of treatment, the change from baseline in serum potassium, and the mean dose of patiromer were similar between groups. Veltassa can therefore be taken with or without food. Section 5.1 and 4.2 of the SmPC were updated accordingly. For completeness the percentage of patients receiving RAAS inhibitor therapy with CKD, diabetes mellitus and heart failure from phase 2 and 3 clinical studies has been included in section 5.1 of the SmPC. Section 4.5 was updated to reflect that as patiromer is not absorbed or metabolised by the body, there are limited effects on the function of other medicinal products. |
| PSUSA/10618 /201810 | Periodic Safety Update EU Single assessment - patiromer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16/05/2019 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0008/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/01/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.z - Change in manufacture of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                                                                                                                      |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10618 /201804 | Periodic Safety Update EU Single assessment - patiromer                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31/10/2018 | n/a | PRAC Recommendation - maintenance |
| IB/0006             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                               | 10/09/2018 | n/a |                                   |
| IA/0004/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 18/07/2018 | n/a |                                   |
| PSUSA/10618 /201710 | Periodic Safety Update EU Single assessment - patiromer                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 17/05/2018 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IA/0003/G   | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                     | 11/04/2018   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IAIN/0001/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 16/11/2017   | n/a   |